Skip to main content
    I

    iBio, Inc. Common Stock (IBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.71
    -0.02 (-3.42%)

    Market Cap: $51.55M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    iBio, Inc. Common Stock (IBIO) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to iBio, Inc. Common Stock are ImageneBio (IMA), Biomea Fusion (BMEA) and Instil Bio (TIL). By market cap, iBio, Inc. Common Stock ranks 6th of the 13 companies on this page; Coherus BioSciences (CHRS) is the largest at $81.21M.

    Peer Comparison

    IBIO's revenue growth of 975.0% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    iBio, Inc. Common Stock (IBIO)$51.55MN/A735.4x0.0%N/A975.0%0.00%
    ImageneBio, Inc. (IMA)$43.22MN/A68.5x0.0%N/A0.0%0.00%
    Biomea Fusion Inc (BMEA)$42.31MN/AN/A0.0%N/A0.0%0.00%
    Instil Bio Inc. (TIL)$41.23MN/AN/A0.0%-11.9%0.0%0.00%
    Connect Biopharma Holdings Ltd (CNTB)$42.65MN/A13.6x0.0%N/A5667.0%0.00%
    INmune Bio Inc (INMB)$32.51MN/AN/A0.0%N/A257.1%0.00%
    Fortress Biotech Inc (FBIO)$62.70M0.7x0.8x143.1%57.0%8.7%0.00%
    XBiotech Inc (XBIT)$59.76MN/AN/A0.0%N/A-93.3%0.00%
    Mink Therapeutics Inc (INKT)$47.95MN/A236.3x0.0%N/A0.0%0.00%
    Coherus BioSciences Inc (CHRS)$81.21MN/A1.5x-253.4%-144.8%23.4%0.00%
    Oncolytics Biotech Inc (ONCY)$48.51MN/AN/A0.0%N/A0.0%0.00%
    MAIA Biotechnology Inc. (MAIA)$61.75MN/AN/A0.0%N/A0.0%0.00%
    Gossamer Bio Inc (GOSS)$67.10MN/A0.9x-159.5%147.4%189.1%0.00%
    Peer median$48.23M0.7x7.5x0.0%22.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to iBio, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    ImageneBio, Inc. (IMA)
    ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases.
    IMA competitors
    Biomea Fusion Inc (BMEA)
    Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat...
    BMEA competitors
    Instil Bio Inc. (TIL)
    Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients.
    TIL competitors
    Connect Biopharma Holdings Ltd (CNTB)
    Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators...
    CNTB competitors
    INmune Bio Inc (INMB)
    INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease...
    INMB competitors
    Fortress Biotech Inc (FBIO)
    Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products.
    FBIO competitors
    XBiotech Inc (XBIT)
    XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases.
    XBIT competitors
    Mink Therapeutics Inc (INKT)
    MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic...
    INKT competitors
    Coherus BioSciences Inc (CHRS)
    Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States.
    CHRS competitors
    Oncolytics Biotech Inc (ONCY)
    Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer.
    ONCY competitors
    MAIA Biotechnology Inc. (MAIA)
    MAIA Biotechnology Inc. is an innovative biotechnology company focused on developing cutting-edge cancer therapies that significantly improve patient outcomes...
    MAIA competitors
    Gossamer Bio Inc (GOSS)
    Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing...
    GOSS competitors

    Frequently Asked Questions About IBIO

    Who are iBio, Inc. Common Stock's main competitors?

    The companies most similar to iBio, Inc. Common Stock include ImageneBio (IMA), Biomea Fusion (BMEA), Instil Bio (TIL), Connect Biopharma Holdings (CNTB) and INmune Bio (INMB), listed from the closest match.

    Who is iBio, Inc. Common Stock's biggest competitor?

    Coherus BioSciences (CHRS) is the largest of the similar companies at $81.21M; ImageneBio (IMA) is the closest match by business profile, size, sector and industry.

    How does IBIO stock compare with its competitors?

    IBIO's P/S is 735.4x against a peer median of 7.5x; its net margin is 0.0% against a peer median of 0.0%.

    Which of iBio, Inc. Common Stock's competitors pays a higher dividend?

    iBio, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is iBio, Inc. Common Stock bigger than its competitors?

    No. iBio, Inc. Common Stock is 6th by market cap among the 13 companies on this page; the largest is Coherus BioSciences (CHRS) at $81.21M.